Impact of IL-12 in Cancer

Author(s): Xinjie Lu*.

Journal Name: Current Cancer Drug Targets

Volume 17 , Issue 8 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Background: Interleukin 12 (IL-12) is a pleiotropic cytokine that plays an essential role in Th1-type immune response against cancer, a condition where cells in a particular part of the body grow and reproduce uncontrollably.

Methods: In this review, we describe the structural features of IL-12 family and their roles involved in cancer.

Results: IL-12 has been demonstrated to regulate both innate (natural killer cells) and adaptive (cytotoxic T lymphocytes) immunities in cancer therapy. This cytokine has been proposed as a potential new agent to be developed in cancer immunotherapy studies due to its impressive antitumor effects in many animal models. In addition, the antitumor activity of IL-12 can be efficiently induced by itself as well as significantly improved by its combination with various treatment modalities including antibodies, antiangiogenic agents, radiotherapy, adoptive therapy, and anti-tumor vaccines.

Conclusion: IL-12 has potential roles in anticancer therapy. The advantages of using immunotherapeutic approaches in clinical trials have been reported recently. However, the mechanisms to underlay the immunoregulation and antitumor activities of IL-12 itself, as well as its combination, remain under investigation.

Keywords: IL-12, NK cells, cancer, Th1 pathway, receptor, immunotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [682 - 697]
Pages: 16
DOI: 10.2174/1568009617666170427102729
Price: $65

Article Metrics

PDF: 107
HTML: 22